OBJECTIVE: To explore benchmarks for future consolidation strategies, we evaluated a strictly defined (normal CA-125 and normal CT) second-complete-remission (CR) ovarian cancer population for 1) the median progression-free survival (PFS), 2) the frequency with which second remission exceeds first, and 3) the proportion of patients in remission at given time points. METHODS: Retrospective sampling was carried out at Memorial Sloan-Kettering (10/1993-12/2000) and the Royal Marsden Hospital (1/1995-4/2003) for the following: histological confirmation and elevated CA-125 at diagnosis; primary surgery; first-and second-line platinum-based chemotherapy with CR; and no maintenance therapy. RESULTS: In 35 patients 1) the duration of first PFS was 17.8 months (95% CI, 13.2-24.5 months) and second PFS was 10.8 months (95% CI, 9.6-12.2 months); 2) the number of patients with second response longer than first was 3/35 (9%); 3) the proportion of patients remaining in second complete remission was 100% (3 months), 100% (6 months), 83% (9 months), 34% (12 months), 23% (15 months) and 8.6% (18 months), respectively. CONCLUSION: 1) The median PFS from second complete remission is short. 2) A second response is rarely longer than the first even in this second CR population. 3) The number of patients with a second response longer than the first, or the proportion of patients remaining in complete remission at given time points could be evaluated as an outcome measure in future studies.
OBJECTIVE: To explore benchmarks for future consolidation strategies, we evaluated a strictly defined (normal CA-125 and normal CT) second-complete-remission (CR) ovarian cancer population for 1) the median progression-free survival (PFS), 2) the frequency with which second remission exceeds first, and 3) the proportion of patients in remission at given time points. METHODS: Retrospective sampling was carried out at Memorial Sloan-Kettering (10/1993-12/2000) and the Royal Marsden Hospital (1/1995-4/2003) for the following: histological confirmation and elevated CA-125 at diagnosis; primary surgery; first-and second-line platinum-based chemotherapy with CR; and no maintenance therapy. RESULTS: In 35 patients 1) the duration of first PFS was 17.8 months (95% CI, 13.2-24.5 months) and second PFS was 10.8 months (95% CI, 9.6-12.2 months); 2) the number of patients with second response longer than first was 3/35 (9%); 3) the proportion of patients remaining in second complete remission was 100% (3 months), 100% (6 months), 83% (9 months), 34% (12 months), 23% (15 months) and 8.6% (18 months), respectively. CONCLUSION: 1) The median PFS from second complete remission is short. 2) A second response is rarely longer than the first even in this second CR population. 3) The number of patients with a second response longer than the first, or the proportion of patients remaining in complete remission at given time points could be evaluated as an outcome measure in future studies.
Authors: J-M Ferrero; B Weber; J-F Geay; D Lepille; H Orfeuvre; M Combe; F Mayer; B Leduc; H Bourgeois; D Paraiso; E Pujade-Lauraine Journal: Ann Oncol Date: 2006-11-15 Impact factor: 32.976
Authors: Don S Dizon; Martee L Hensley; Elizabeth A Poynor; Paul Sabbatini; Carol Aghajanian; Amanda Hummer; Ennapadam Venkatraman; David R Spriggs Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen Journal: J Clin Oncol Date: 2003-07-14 Impact factor: 44.544
Authors: Don S Dizon; Jakob Dupont; Sibyl Anderson; Paul Sabbatini; Amanda Hummer; Carol Aghajanian; David Spriggs Journal: Gynecol Oncol Date: 2003-12 Impact factor: 5.482
Authors: M K B Parmar; J A Ledermann; N Colombo; A du Bois; J-F Delaloye; G B Kristensen; S Wheeler; A M Swart; W Qian; V Torri; I Floriani; G Jayson; A Lamont; C Tropé Journal: Lancet Date: 2003-06-21 Impact factor: 79.321
Authors: Alexia Iasonos; Paul Sabbatini; David R Spriggs; Carol A Aghajanian; Roisin E O'Cearbhaill; Martee L Hensley; Howard T Thaler Journal: Int J Gynecol Cancer Date: 2012-01 Impact factor: 3.437
Authors: Andreas Hallqvist; Karin Bergmark; Tom Bäck; Håkan Andersson; Pernilla Dahm-Kähler; Mia Johansson; Sture Lindegren; Holger Jensen; Lars Jacobsson; Ragnar Hultborn; Stig Palm; Per Albertsson Journal: J Nucl Med Date: 2019-01-25 Impact factor: 10.057